Frequently Asked Questions (FAQ)

Are cognitive measurement biofeedback tests covered by insurance?

EEG measurement and analysis is covered by CMS and most insurance companies. There are six different CPT codes that are generally reimbursed in conjunction with proper ICD-10 codes. For a list of applicable CPT and ICD-10 codes, contact Evoke Neuroscience at support@evokeneuroscience.com.

Is eVox® neurotherapy covered by insurance?

Neurotherapy is reimbursed by some insurance providers. It is also commonly performed as a cash-pay procedure. For a list of applicable CPT and ICD-10 codes, and information about national rates for patient-pay procedures, contact Evoke Neuroscience at support@evokeneuroscience.com.

What is the eVox system?
  • faqThe eVox system is a device to help physicians objectively measure and optimally manage memory loss, cognitive impairment, and other stress-related conditions.
  • The eVox system is a state-of-the-art hardware and software system that allows for an objective and expansive functional measurement of the brain and cognition using electroencephalography (EEG), electrocardiography (ECG), and event-related potential (ERP).
  • The eVox system is designed to help facilitate early and continuous understanding of changes in cognitive function. As a result, it can deliver quantitative information for physicians to provide informed medical, nutritional, and behavioral interventions to help optimize patient outcomes.
  • eVox allows primary care physicians and specialists to monitor dynamic changes that take place throughout the brain during cognitive processing tasks.
    • The eVox system is the only system available that combines these sophisticated assessment tools into one portable, easy-to-use workstation that generates a cognitive assessment report that informs of a more individualized biofeedback protocol.
    • eVox provides a report which is a useful tool to the clinician as an adjunct to traditional subjective clinical assessment, as it provides objective data with high degree of sensitivity in detecting subtle variations in brain activity.
  • eVox does not require a physician to operate the device.

Why are EEG, ECG, and ERP measures important?
  • EEG shows how well-functioning brain regions compensate for dysfunctional regions which allows specific determination of varied treatments and an ability to track changes over time.1 EEG analysis can identify the specific electrical frequency markers of physiological aging and memory performance.2-4
  • ECG is used to calculate heart rate variability (HRV) measures that are linked to cognitive decline, and anxiety and stress related conditions.5 Low HRV predicts heart disease incidence and is linked to cognitive impairment.6-10
  • Event-Related Potentials (ERP) measure real-time cognitive processing that is essential for healthy brain functions and helps detect early risk measures of dementia, including:
    • Decision making, organization, attention, and memory11-16
    • Visual processing17
    • Language processing18,19
  • ERP testing measures inattention, impulsivity, motor processing speed, and reaction time linked to cognitive impairment.20

What is included in the eVox system?
  • The eVox system includes the workstation hardware, software, and disposables to collect EEG, ECG, and ERP data for both cognitive assessment reporting and neurotherapy applications.
  • The eVox system initially comes with a package of “report credits” for you to get started. A “report credit” is required each time you run a cognitive assessment test on a patient. This enables the workstation to perform the test and automatically generates a summary and detailed cloud-based eVox report.
  • The hardware includes a laptop computer (pre-downloaded with eVox proprietary software), eVox amplifier, patient response button, USB charging cable, 2 reusable EEG/ECG recording caps, and ear buds.
  • Disposables include electro-conductive gel, syringe, blunt tip needles, alcohol swabs, ECG sensors, NuPrep skin preparatory cream, and orange sticks for cap cleaning. The stocking order of disposables is cost effective and supports approximately 15 to 20 patient recordings.

Where can I purchase additional report credits and testing supplies for my eVox system?
  • Additional supplies are available for purchase from Electro Cap International by calling 800.527.2193. A complete list of supplies is provided with your eVox system.
  • You can purchase additional report credits on the secure and HIPAA compliant Evoke Neuroscience web portal at portal.evokeneuroscience.com.

Schedule a Free eVox Clinical Demonstration in Your Office

Schedule a Free eVox Clinical
Demonstration in Your Office





Please contact me to schedule a free eVox Clinical Demonstration in my office.*

Type of Practice:

Practice Address:

captcha

*Demonstration availability dependent upon Evoke Neuroscience representative coverage in your market.

References
  1. Dujardin K, Bourriez JL, Guieu DJ. Event-related desynchronization (ERD) patterns during verbal memory tasks: Effect of age. International Journal of Psychophysiology. 1994;16(1):17-27.
  2. Dujardin K, Bourriez JL, Guieu DJ. Event related desynchronization (ERD) patterns during memory processes: Effects of aging and task difficulty. Electroencephalography and Clinical Neurophysiology. 1995;96(2):169-182.
  3. Klass DW, Brenner RP. Electroencephalography of the elderly. Journal of Clinical Neurophysiology. 1995;12(2):116-131.
  4. Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: A review and analysis. Brain Research Reviews. 1999;29(2-3):169-195.
  5. Shah AJ, Su S, Veledar E, et. al. Is heart rate variability related to memory performance in middle-aged men? Psychosomatic Medicine. 2011;73(6):475-482.
  6. Liao D, Cai J, Rosamond WD, et. al. Cardiac autonomic function and incident coronary heart disease: A population-based case-cohort study. American Journal of Epidemiology. 1997;45:696-706.
  7. Karlamangla AS, Singer BH, Chodosh J, McEwen BS, Seeman TE. Urinary cortisol excretion as a predictor of incident cognitive impairment. Neurobiological Aging. 2005;26(Suppl.):80-84.
  8. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999;282:254-60.
  9. Kim DH, Lipsitz LA, Ferrucci L, et al. Association between reduced heart rate variability and cognitive impairment in older disabled women in the community: Women’s health and aging study. Journal of American Geriatrics Society. 2006;554:1751-1757.
  10. Zulli R, Nicosia F, Borroni B, et al. QT dispersion and heart rate variability abnormalities in Alzheimer’s disease and in mild cognitive impairment. J. of American Geriatrics Society. 2005;53(12):2135-2139.
  11. Olichney JM, Morris SK, Ochoa C, et al. Abnormal verbal event related potentials in mild cognitive impairment and incipient Alzheimer’s disease. Journal of Neurology Neurosurgery and Psychiatry. 2002;73(4):377-384.
  12. Polich J, Corey-Bloom J. Alzheimer’s disease and P300: Review and evaluation of task and modality. Current Alzheimer Research. 2005;2(5):515-525.
  13. Polich J. Updating P300: An integrative theory of P3a and P3b. Clinical Neurophysiology. 2007;118:2128-2148.
  14. Bennys K, Portet F, Touchon J, Rondouin G. Diagnostic value of event-related evoked potentials N200 and P300 subcomponents in early diagnosis of Alzheimer’s disease and mild cognitive impairment. J. of Clinical Neurophysiology. 2007;24(5):405-12.
  15. Olichney JM, Iragui VJ, Salmon DP, Riggins BR, Morris SK, Kutas M. Absent event-related potential (ERP) word repetition effects in mild Alzheimer’s disease. Clinical Neurophysiology. 2006;117(6):1319-1330.
  16. Olichney JM, Taylor JR, Gatherwright J, et al. Patients with MCI and N400 or P600 abnormalities are at very high risk for conversion to dementia. Neurology. 2008;70(19):1763-70.
  17. Wright C, Furlongm P. Visual evoked potentials in elderly patients with primary or multi-infarct dementia. British Journal of Psychiatry. 1988;152:679-682.
  18. Gorus E, De Raedt R, Lambert M, Lemper JC, Mets T. Reaction times and performance variability in normal aging, mild cognitive impairment, and Alzheimer's disease. J Geriatr Psychiatry Neurol. 2008;21(3):204-18.
  19. Moretti DV, Babiloni C, Binetti G, et al. Individual analysis of EEG frequency and band power in mild Alzheimer’s disease. Clinical Neurophysiology. 2004;115(2):299-308.
  20. Pfurtscheller G, Lopes da Silva FH. Event-related EEG/MEG synchronization and desynchronization: basic principles. Clinical Neurophysiology. 1999;110(11): 1842-1857, 1999.
ISO 13485 CertifiedEvoke Neuroscience is an FDA Registered Establishment and is compliant with all FDA standards, meaning that all of our business policies, procedures, and products align with the FDA and are subject to FDA audits. In addition, our facility goes through a rigorous and ongoing auditing process and is certified by BSI (ISO 13485:2003).

© Copyright 2017 — Evoke Neuroscience, Inc.

Terms & Conditions | Privacy Policy | Interest-based Ads


inc-500ISO 13485 CertifiedThe eVox system is a biofeedback device not intended to act as a diagnostic tool. The assessment component of the device provides valuable information on patient physiology associated with underlying neuropsychiatric pathologies that physicians can use as a tool, along with medical expertise and the patients’ relevant medical history, to make better informed decisions regarding a patient’s health and to plan individualized biofeedback.

Log in with your credentials

Forgot your details?